Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate

By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.

Having identified a novel atypical Protein Kinase C (aPKC) inhibitor preclinical candidate that Teva Pharmaceutical Industries Ltd. will move into the clinic, the Israeli drug maker and Cancer Research Technology Ltd. are starting a new project to find and develop drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

Their collaboration started in March 2010 when Cancer Research Technology inked a deal with Cephalon Inc. on developing small-molecule...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D